Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms
BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.3, pp.351-355, 2014 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 68 Issue: 3
- Publication Date: 2014
- Doi Number: 10.1016/j.biopha.2013.09.007
- Journal Name: BIOMEDICINE & PHARMACOTHERAPY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.351-355
- Keywords: Etoposide, Chemoresistance, Breast cancer, TOPOISOMERASE-II ACTIVITY, MULTIDRUG-RESISTANCE, GENE-EXPRESSION, SENSITIVITY, TOPBP1
- Middle East Technical University Affiliated: Yes
Abstract
Purpose: Acquired or intrinsic drug resistance is one of the major handicaps in the success of chemotherapy. Etoposide is a topoisomerase II poison widely used in chemotherapy. Similar to other topoisomerase inhibitors and DNA damaging agents, resistance to etoposide may arise as a result of alterations in target expression and activity, increased drug efflux and alterations in DNA damage response mechanisms. Here, we tested the involvement of such mechanisms in etoposide-resistant MCF-7 breast cancer cells.